フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
ORLANDO, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Today’s featured company is a simple story. It’s a uranium...
Company Announcement IND for HuMax(R)-TF-ADC submitted to FDA Genmab's first IND submission for antibody-drug conjugate (ADC) product...
Company Announcement Genentech and Biogen Idec refused re-hearing in Arzerra patent infringement case COPENHAGEN, Denmark, July 15, 2013...
Company Announcement First Phase III study with subcutaneous formulation of ofatumumab Ofatumumab to be investigated in new autoimmune...
Media Release Antibody-drug conjugate (ADC) to be developed for cancer Combines strength of HuMax(R)-TAC with next generation...
Company Announcement Teprotumumab (RG1507) to be investigated for new indication River Vision Development Corporation to conduct...
Company Announcement Genmab establishes Sponsored Level 1 ADR program Genmab ADRs can be traded on US over-the-counter (OTC) market...
Company Announcement Median 22.4 month progression free survival in patients treated with ofatumumab plus chlorambucil, an improvement of...
Company Announcement Genentech and Biogen Idec have filed for re-hearing in the United States COPENHAGEN, Denmark, May 17, 2013 (GLOBE...
COPENHAGEN, Denmark, May 7, 2013 (GLOBE NEWSWIRE) -- Interim Report First Quarter 2013 Arzerra(r) received approval in Japan Arzerra net...
Company Announcement 95% overall response rate and 43% complete response rate in patients with previously untreated chronic lymphocytic...
Company Announcement Daratumumab receives Breakthrough Therapy Designation in double refractory multiple myeloma Potential for...
Company Announcement Arzerra worldwide net sales in Q1 2013 totaled GBP 20.5 million Genmab expects royalty payment of DKK 36 million...
Company Announcement At Genmab A/S' Annual General Meeting held today on April 17, 2013 the Annual Report for 2012 was...
Company Announcement Final ruling of U.S. Court of Appeals in favor of GSK in Arzerra patent infringement case COPENHAGEN, Denmark, April...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約